Stephen Ehrenzeller
Research
Publications
2026
Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes.
Bhagchandani SH, Ehrenzeller S, Pires IS, Chaudhary N, Booth CJ, Kwon DI, Koutsioumpa C, Baker CA, Laxton C, Santos Guedes de Sá K, Matthews C, Gill P, Li S, Olszowka A, Hudak A, Fischer S, Bayarri-Olmos R, Hooper WB, Iwasaki A. Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes. Sci Immunol 2026, 11: eaea6419. PMID: 42319912, DOI: 10.1126/sciimmunol.aea6419.Peer-Reviewed Original ResearchThis study investigates a novel vaccine strategy using BEACONs, a mucosal adjuvant, to enhance localized immunity and protect against genital herpes by boosting tissue-resident T cells and antibodies.A novel manganese glycerophosphate vaccine gel elicits broad and durable immunity across an aged and pox virus model
Islam M, Ontiveros-Padilla L, Ehrenzeller S, Middleton D, Roque J, Murphy C, Lukesh N, Hendy D, Pena E, Stack R, Polacheck W, Bachelder E, Ainslie K. A novel manganese glycerophosphate vaccine gel elicits broad and durable immunity across an aged and pox virus model. Nanoscale 2026, 18: 10795-10809. PMID: 42017804, DOI: 10.1039/d5nr03936c.Peer-Reviewed Original ResearchHarnessing mucosal immunity for protective vaccines
Kwon D, Bhagchandani S, Ehrenzeller S, Iwasaki A. Harnessing mucosal immunity for protective vaccines. Nature Reviews Immunology 2026, 26: 507-524. PMID: 41699393, PMCID: PMC13088808, DOI: 10.1038/s41577-026-01273-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
Induction of Antigen-Specific Tolerance in a Multiple Sclerosis Model without Broad Immunosuppression
Stiepel R, Simpson S, Lukesh N, Middleton D, Hendy D, Ontiveros-Padilla L, Ehrenzeller S, Islam J, Pena E, Carlock M, Ross T, Bachelder E, Ainslie K. Induction of Antigen-Specific Tolerance in a Multiple Sclerosis Model without Broad Immunosuppression. ACS Nano 2025, 19: 3764-3780. PMID: 39812522, PMCID: PMC12740341, DOI: 10.1021/acsnano.4c14698.Peer-Reviewed Original Research
2024
Comparison of emulsion and spray methods for fabrication of rapamycin-loaded acetalated dextran microparticles
Ehrenzeller S, Lukesh N, Stiepel R, Middleton D, Nuzzolo S, Tate A, Batty C, Bachelder E, Ainslie K. Comparison of emulsion and spray methods for fabrication of rapamycin-loaded acetalated dextran microparticles. RSC Pharmaceutics 2024, 1: 727-741. PMID: 39415944, PMCID: PMC11474811, DOI: 10.1039/d4pm00054d.Peer-Reviewed Original ResearchMicroparticles incorporating dual apoptotic factors to inhibit inflammatory effects in macrophages
Simpson S, Middleton D, Lukesh N, Islam M, Ehrenzeller S, Bachelder E, Ainslie K. Microparticles incorporating dual apoptotic factors to inhibit inflammatory effects in macrophages. Journal Of Pharmaceutical Sciences 2024, 113: 3196-3205. PMID: 38852674, PMCID: PMC11560629, DOI: 10.1016/j.xphs.2024.05.030.Peer-Reviewed Original Research
2022
A predictive mechanistic model of drug release from surface eroding polymeric nanoparticles
Stiepel R, Pena E, Ehrenzeller S, Gallovic M, Lifshits L, Genito C, Bachelder E, Ainslie K. A predictive mechanistic model of drug release from surface eroding polymeric nanoparticles. Journal Of Controlled Release 2022, 351: 883-895. PMID: 36208792, PMCID: PMC10407653, DOI: 10.1016/j.jconrel.2022.09.067.Peer-Reviewed Original Research